genia tagger: 222('46\\.2\\\xe2\\\x80\\\x9358\\.4', 10)
('inhibitor\\-1\\.', 1)
('all', 72)
('1\\.39', 4)
('0\\.67\\\xe2\\\x80\\\x931\\.86', 2)
('137', 2)
('135', 18)
('0\\.59\\\xe2\\\x80\\\x931\\.64', 2)
('138', 18)
('1\\.35', 4)
('2\\.88', 3)
('24', 11)
('25', 37)
('26', 17)
('27', 21)
('vte', 161)
('21', 7)
('22', 31)
('23', 13)
('\\?', 472)
('\\<', 63)
('29', 17)
('hrs', 9)
('0\\.55', 18)
('0\\.56', 6)
('n', 2594)
('0\\.50', 5)
('4', 338)
('1\\.33\\\xe2\\\x80\\\x936\\.00', 2)
('96', 10)
('0\\.58', 12)
('antithrombin', 2)
('\\(', 479)
('\\)', 479)
('0\\.57', 6)
('risk', 95)
('\\[', 51)
('0\\.78\\\xe2\\\x80\\\x932\\.49', 2)
('0\\.42\\\xe2\\\x80\\\x931\\.31', 2)
('provoked', 199)
('125', 2)
('129', 2)
('0\\.76\\\xe2\\\x80\\\x932\\.26', 2)
('59', 18)
('58', 52)
('61', 19)
('55', 33)
('hdl-c', 68)
('57', 13)
('b100', 28)
('proteins', 7)
('50', 17)
('53', 24)
('52', 10)
('0\\.25', 2)
('54', 24)
('0\\.29', 4)
('0\\.51', 4)
('n\\=161', 1)
('ldl-c', 17)
('0\\.81', 10)
('apolipoprotein', 23)
('0\\.47\\\xe2\\\x80\\\x931\\.43', 2)
('51', 10)
('114', 18)
('110', 2)
('113', 4)
('proportional', 4)
('low-density', 10)
('iqr', 2)
('119', 4)
('1\\.31', 12)
('0\\.56\\\xe2\\\x80\\\x931\\.95', 2)
('factors', 4)
('10\\.8', 2)
('18', 13)
('3', 378)
('0\\.31', 6)
('7', 310)
('0\\.35', 2)
('3\\.58', 5)
('fragments', 2)
('0\\.91', 4)
('0\\.92', 10)
('lipid', 93)
('0\\.96', 8)
('0\\.97', 10)
('0\\.98', 8)
('0\\.99', 12)
('20', 20)
('0\\.57\\\xe2\\\x80\\\x931\\.83', 2)
('108', 2)
('biomarkers', 31)
('95', 162)
('ratio', 113)
('107', 20)
('38', 28)
('non-users', 44)
('33', 20)
('cox', 8)
('31', 28)
('30', 14)
('37', 6)
('36', 10)
('35', 31)
('34', 15)
('trial', 4)
('0\\.45\\\xe2\\\x80\\\x931\\.27', 2)
('0\\.0013', 2)
('1\\.69\\\xe2\\\x80\\\x937\\.58', 5)
('poisson', 2)
('0\\.06', 6)
('0\\.04', 4)
('0\\.03', 6)
('0\\.02', 10)
('ci', 239)
('0\\.0028', 2)
('0\\.68', 4)
('0\\.65', 6)
('0\\.67', 18)
('0\\.66', 12)
('0\\.61', 6)
('0\\.60', 8)
('1\\.71', 4)
('2\\.82', 2)
('60', 28)
('randomized', 18)
('0\\.66\\\xe2\\\x80\\\x931\\.88', 2)
('64', 6)
('65', 16)
('66', 18)
('67', 20)
('table', 24)
('0\\.82', 6)
('0\\.55\\\xe2\\\x80\\\x931\\.73', 2)
('0\\.80', 6)
('0\\.43\\\xe2\\\x80\\\x931\\.33', 2)
('2', 465)
('1\\.9', 18)
('6', 318)
('0\\.10', 4)
('1\\.4', 41)
('1\\.1', 50)
('1\\.0', 132)
('1\\.3', 42)
('mg\\/dl', 56)
('0\\.40', 4)
('1\\.29\\\xe2\\\x80\\\x936\\.42', 3)
('0\\.78', 16)
('hr', 49)
('0\\.77', 10)
('0\\.74', 10)
('bmi', 9)
('0\\.70', 10)
('1\\.5', 25)
('0\\.41\\\xe2\\\x80\\\x931\\.19', 2)
('lipoprotein', 45)
('0\\.001', 4)
('iii', 4)
('0\\.007', 2)
('11', 59)
('10', 87)
('12', 19)
('16', 30)
('characteristic', 8)
('0\\.59', 8)
('46\\.2', 20)
('cis', 2)
('\\%', 141)
('32', 22)
('1\\.2', 35)
('0\\.75\\\xe2\\\x80\\\x932\\.41', 2)
('and', 326)
('models\\.', 4)
('41', 18)
('1\\.25', 4)
('0\\.41', 6)
('112', 2)
('0\\.72\\\xe2\\\x80\\\x934\\.05', 2)
('1\\.11', 4)
('regression', 4)
('1\\.12', 2)
('0\\.44\\\xe2\\\x80\\\x931\\.41', 2)
('48', 10)
('49', 16)
('46', 26)
('44', 10)
('42', 19)
('43', 18)
('40', 14)
('prothrombin', 2)
('1', 1017)
('0\\.76', 8)
('5', 558)
('1\\.61', 4)
('activator', 1)
('0\\.34', 2)
('144', 2)
('0\\.75', 8)
('users', 99)
('models', 8)
('0\\.95\\\xe2\\\x80\\\x932\\.73', 2)
('hazard', 109)
('0\\.38\\\xe2\\\x80\\\x931\\.17', 2)
('77', 14)
('76', 10)
('ht', 43)
('70', 19)
('hemostatic', 3)
('1\\.05', 2)
('1\\.02', 6)
('78', 18)
('\xe2\x80\x93', 334)
('80', 12)
('98', 14)
('plasminogen', 1)
('0\\.54\\\xe2\\\x80\\\x931\\.79', 2)
('or', 440)
('portion', 7)
('unadjusted', 10)
('0\\.31\\\xe2\\\x80\\\x930\\.97', 4)
('0\\.71\\\xe2\\\x80\\\x932\\.22', 2)


spacy + metamap: 392('hormone therapy', 69)
('disease control', 1)
('activated', 3)
('resistance', 2)
('follow', 29)
('adjustment', 2)
('centers', 1)
('eligible', 1)
('technique', 1)
('kg\\/m2', 12)
('pulmonary embolism', 8)
('endogenous', 1)
('hormone', 71)
('risk', 95)
('difference', 4)
('categories', 4)
('body mass index', 21)
('issue', 1)
('large', 13)
('obesity', 2)
('occurrence', 2)
('trend', 44)
('direct', 8)
('second', 9)
('value', 14)
('established', 5)
('current', 19)
('white race', 2)
('new', 4)
('increasing', 20)
('contrast', 4)
('apolipoprotein a', 10)
('cohorts', 4)
('full', 17)
('risk determinant', 2)
('\\>5', 10)
('men', 72)
('others', 5)
('november', 1)
('strong', 4)
('extreme', 10)
('institutional review board', 1)
('self-report', 2)
('endpoints', 2)
('healthy', 4)
('31', 28)
('reports', 10)
('prior', 7)
('apolipoprotein', 23)
('published', 3)
('reagents', 1)
('studies', 3)
('biomarkers', 31)
('classification', 6)
('proportion', 6)
('vii', 5)
('primary prevention', 1)
('total', 35)
('cox models', 2)
('use', 154)
('positive', 7)
('hospital', 5)
('two', 2)
('aspirin', 3)
('3 months', 4)
('successful', 4)
('mismatch', 2)
('known', 5)
('cases', 2)
('97', 16)
('women', 32)
('high', 35)
('mg', 56)
('endpoint', 3)
('unadjusted incidence rate', 6)
('work', 1)
('measures', 7)
('risk factors', 3)
('inhibitor', 1)
('example', 2)
('heart', 3)
('scan', 4)
('sample', 10)
('activated protein c', 2)
('information', 1)
('end', 58)
('effect modifier', 5)
('discussion', 2)
('means', 2)
('venous', 17)
('coronary heart disease', 2)
('epidemiologic', 3)
('collection', 4)
('blood', 8)
('hemostatic', 3)
('data', 14)
('third', 4)
('biomarker', 45)
('first', 12)
('order', 6)
('sd', 8)
('years', 38)
('report', 28)
('vitamin e', 3)
('p-value', 12)
('vte', 161)
('cardiovascular events', 1)
('symptoms', 2)
('absence', 4)
('decreased', 2)
('main', 6)
('physicians', 2)
('non', 46)
('blood samples', 1)
('records', 4)
('therapy', 71)
('effects', 4)
('not', 23)
('association', 30)
('venography', 2)
('term', 7)
('equality', 18)
('proteins', 7)
('magnitude', 2)
('investigators', 1)
('weight', 2)
('independent', 2)
('use of', 4)
('measure', 18)
('laboratory', 1)
('balance', 6)
('event', 26)
('category', 2)
('borderline', 4)
('increase', 40)
('participants', 14)
('trauma', 5)
('evaluation', 2)
('nitrogen', 1)
('standard', 3)
('hazard', 109)
('care', 3)
('definition', 2)
('interaction', 36)
('period', 6)
('abbreviations', 4)
('plasminogen', 1)
('cardiovascular disease', 2)
('prospective', 11)
('variables', 10)
('number', 4)
('one', 75)
('defects', 2)
('total cholesterol', 29)
('little', 3)
('introduction', 1)
('recent', 1)
('apo a', 50)
('relationship', 26)
('explanation', 2)
('continuous', 4)
('part', 21)
('authors', 2)
('july', 1)
('population', 10)
('kind', 2)
('patients', 4)
('future', 24)
('stratified', 8)
('time period', 2)
('medical records', 2)
('boston', 1)
('correction', 1)
('null', 2)
('quartile', 2)
('current smoker', 2)
('chest', 2)
('potential', 1)
('provoked', 199)
('modifier', 5)
('altered', 2)
('opposite', 2)
('incidence', 32)
('significant', 23)
('whs', 3)
('autopsy', 2)
('3 days', 2)
('kg', 13)
('observation', 9)
('clear', 4)
('factor viii', 2)
('traditional', 1)
('unadjusted', 10)
('randomized trial', 1)
('chances', 2)
('\\/dl', 56)
('impact', 2)
('basel', 27)
('only', 10)
('lipids', 13)
('factor', 11)
('permission', 2)
('overall', 6)
('population distributions', 2)
('blood sampling', 2)
('protein c', 26)
('secondary', 3)
('approach', 2)
('median', 5)
('alteration', 6)
('activity', 1)
('switzerland', 1)
('committee', 4)
('national', 1)
('observed', 27)
('individual', 2)
('result', 10)
('surgery', 5)
('immobilization', 1)
('subject', 3)
('score', 6)
('computed tomography', 2)
('angiogram', 2)
('risks', 4)
('variability', 2)
('tables', 2)
('initially', 3)
('analyzer', 3)
('incident', 11)
('hypothesis', 4)
('problem', 2)
('study protocol', 1)
('variance', 4)
('placebo', 1)
('expression', 1)
('ci', 239)
('cancer', 4)
('cox proportional hazards models', 2)
('medical history', 2)
('excess', 2)
('mutations', 1)
('height', 2)
('antithrombin iii', 2)
('roche diagnostics', 2)
('65', 16)
('table', 24)
('basis', 2)
('addition', 2)
('direction', 2)
('hemostasis', 2)
('most significant', 2)
('smoking', 16)
('novel', 1)
('evaluated', 3)
('aim', 1)
('institute', 1)
('ongoing', 1)
('hdl', 68)
('study', 26)
('trend analysis', 4)
('concomitant', 5)
('prevalence', 4)
('characteristics', 6)
('statistical analysis', 2)
('regression', 4)
('cohort', 16)
('different', 2)
('baseline', 26)
('factorial design', 1)
('recurrent', 1)
('same', 1)
('triglycerides', 28)
('randomization', 2)
('largest', 2)
('modification', 1)
('events', 23)
('conflict', 5)
('higher', 5)
('conflicting', 3)
('decedent', 2)
('literature', 2)
('reporting', 6)
('effect', 18)
('levels', 83)
('i-', 4)
('kin', 20)
('subgroups', 2)
('lower', 3)
('apolipoproteins b', 3)
('confidence intervals', 16)
('database', 2)
('changes', 2)
('apolipoproteins', 6)
('well', 9)
('analysis', 26)
('person', 18)
('model', 14)
('adjusted', 45)
('end point', 6)
('study population', 4)
('venous thromboembolism', 13)
('death', 4)
('sample size', 4)
('apolipoprotein b', 6)
('thrombotic', 6)
('treatment', 14)
('plasma', 2)
('associations', 2)
('march', 1)
('increased', 30)
('possible', 6)
('general population', 2)
('finding', 2)
('venous thromboembolic event', 2)
('background', 1)
('sampling', 4)
('case-control study', 4)
('ventilation-perfusion scan', 2)
('standardization', 1)
('55', 33)
('malignancy', 4)
('specific', 5)
('either', 16)
('reduced', 5)
('methods', 2)
('calibrator', 1)
('trends', 18)
('questionnaire', 2)
('investigations', 1)
('limitations', 4)
('core', 7)
('meta-analysis', 1)
('lipid', 93)
('glycerol', 1)
('factor vii', 4)
('panel', 2)
('comparison', 2)
('statistically significant', 17)
('range', 48)
('tailed', 2)
('confidence interval', 18)
('mean', 12)
('objectives', 1)
('ldl cholesterol', 2)
('71', 16)
('presence', 2)
('stratification', 2)
('ultrasound', 2)
('lung', 1)
('proportional', 4)
('measured', 9)
('initial', 5)
('long', 4)
('clinical', 2)
('lowest', 6)
('complete', 5)
('lipid level', 22)
('ht', 43)
('highest', 8)
('hazard ratio', 105)
('deep vein thrombosis', 6)
('characteristic', 8)
('prospective cohort study', 1)
('chi-square test', 4)
('cis', 2)
('distribution', 4)
('similar', 8)
('informed consent', 1)
('follow up', 13)
('deaths', 2)
('evidence', 3)
('follow-up', 14)
('statistical significance', 4)
('risk factor', 5)
('epidemiological', 1)
('triglyceride level', 5)
('percent', 4)
('portion', 7)
('incidence rate', 24)
('blinded', 2)
('test', 34)
('conclusion', 3)
('users', 99)
('models', 8)
('important', 8)
('massachusetts', 2)
('variable', 16)
('3rd', 4)
('age', 25)
('i levels', 5)
('diagnosis', 6)
('time', 10)


total: 590('all', 72)
('hormone therapy', 69)
('disease control', 1)
('activated', 3)
('resistance', 2)
('1\\.39', 4)
('follow', 29)
('0\\.59\\\xe2\\\x80\\\x931\\.64', 2)
('adjustment', 2)
('centers', 1)
('1\\.35', 4)
('eligible', 1)
('iii', 4)
('technique', 1)
('0\\.55', 18)
('0\\.56', 6)
('0\\.57', 6)
('0\\.50', 5)
('0\\.51', 4)
('women', 32)
('0\\.58', 12)
('0\\.59', 8)
('hormone', 71)
('risk', 95)
('0\\.42\\\xe2\\\x80\\\x931\\.31', 2)
('difference', 4)
('categories', 4)
('body mass index', 21)
('venous', 17)
('evaluation', 2)
('large', 13)
('kg\\/m2', 12)
('obesity', 2)
('n\\=161', 1)
('occurrence', 2)
('core', 7)
('trend', 44)
('direct', 8)
('second', 9)
('value', 14)
('46\\.2', 20)
('1\\.31', 12)
('established', 5)
('risk factors', 3)
('current', 19)
('white race', 2)
('new', 4)
('increasing', 20)
('contrast', 4)
('apolipoprotein a', 10)
('cohorts', 4)
('full', 17)
('risk determinant', 2)
('\\>5', 10)
('men', 72)
('108', 2)
('others', 5)
('november', 1)
('strong', 4)
('107', 20)
('extreme', 10)
('institutional review board', 1)
('self-report', 2)
('38', 28)
('33', 20)
('32', 22)
('31', 28)
('30', 14)
('37', 6)
('36', 10)
('35', 31)
('34', 15)
('prior', 7)
('poisson', 2)
('published', 3)
('reagents', 1)
('studies', 3)
('glycerol', 1)
('0\\.68', 4)
('classification', 6)
('0\\.65', 6)
('proportion', 6)
('0\\.67', 18)
('vii', 5)
('primary prevention', 1)
('0\\.60', 8)
('1\\.71', 4)
('concomitant', 5)
('total', 35)
('cox models', 2)
('use', 154)
('positive', 7)
('objectives', 1)
('prevalence', 4)
('two', 2)
('6', 318)
('0\\.10', 4)
('aspirin', 3)
('3 months', 4)
('successful', 4)
('mismatch', 2)
('98', 14)
('0\\.41\\\xe2\\\x80\\\x931\\.19', 2)
('lipoprotein', 45)
('known', 5)
('cases', 2)
('95', 162)
('97', 16)
('96', 10)
('high', 35)
('mg', 56)
('endpoint', 3)
('unadjusted incidence rate', 6)
('work', 1)
('endogenous', 1)
('inhibitor', 1)
('institute', 1)
('statistical analysis', 2)
('heart', 3)
('scan', 4)
('sample', 10)
('activated protein c', 2)
('mg\\/dl', 56)
('information', 1)
('end', 58)
('effect modifier', 5)
('discussion', 2)
('means', 2)
('1', 1017)
('activator', 1)
('coronary heart disease', 2)
('144', 2)
('epidemiologic', 3)
('0\\.95\\\xe2\\\x80\\\x932\\.73', 2)
('hazard', 109)
('3rd', 4)
('independent', 2)
('cardiovascular disease', 2)
('hemostatic', 3)
('data', 14)
('third', 4)
('biomarker', 45)
('or', 440)
('first', 12)
('order', 6)
('sd', 8)
('inhibitor\\-1\\.', 1)
('years', 38)
('equality', 18)
('population distributions', 2)
('137', 2)
('135', 18)
('blood sampling', 2)
('138', 18)
('24', 11)
('25', 37)
('26', 17)
('27', 21)
('vte', 161)
('21', 7)
('22', 31)
('23', 13)
('29', 17)
('symptoms', 2)
('absence', 4)
('decreased', 2)
('main', 6)
('antithrombin', 2)
('1\\.25', 4)
('non', 46)
('stratification', 2)
('0\\.38\\\xe2\\\x80\\\x931\\.17', 2)
('0\\.78\\\xe2\\\x80\\\x932\\.49', 2)
('records', 4)
('example', 2)
('effects', 4)
('not', 23)
('association', 30)
('venography', 2)
('term', 7)
('0\\.45\\\xe2\\\x80\\\x931\\.27', 2)
('vitamin e', 3)
('proteins', 7)
('magnitude', 2)
('0\\.25', 2)
('0\\.29', 4)
('investigators', 1)
('blinded', 2)
('weight', 2)
('apolipoprotein', 23)
('use of', 4)
('measure', 18)
('laboratory', 1)
('80', 12)
('balance', 6)
('event', 26)
('category', 2)
('i levels', 5)
('borderline', 4)
('factors', 4)
('10\\.8', 2)
('increase', 40)
('participants', 14)
('trauma', 5)
('7', 310)
('issue', 1)
('pulmonary embolism', 8)
('standard', 3)
('0\\.57\\\xe2\\\x80\\\x931\\.83', 2)
('collection', 4)
('care', 3)
('definition', 2)
('interaction', 36)
('non-users', 44)
('period', 6)
('abbreviations', 4)
('plasminogen', 1)
('blood', 8)
('prospective', 11)
('0\\.67\\\xe2\\\x80\\\x931\\.86', 2)
('variables', 10)
('number', 4)
('one', 75)
('randomized', 18)
('0\\.66\\\xe2\\\x80\\\x931\\.88', 2)
('defects', 2)
('total cholesterol', 29)
('0\\.82', 6)
('little', 3)
('0\\.55\\\xe2\\\x80\\\x931\\.73', 2)
('introduction', 1)
('2', 465)
('subgroups', 2)
('ldl-c', 17)
('apo a', 50)
('1\\.29\\\xe2\\\x80\\\x936\\.42', 3)
('0\\.78', 16)
('0\\.76', 8)
('0\\.77', 10)
('0\\.74', 10)
('0\\.75', 8)
('0\\.70', 10)
('part', 21)
('authors', 2)
('july', 1)
('population', 10)
('11', 59)
('10', 87)
('kind', 2)
('12', 19)
('16', 30)
('risk factor', 5)
('18', 13)
('patients', 4)
('future', 24)
('risks', 4)
('0\\.75\\\xe2\\\x80\\\x932\\.41', 2)
('time period', 2)
('and', 326)
('lowest', 6)
('questionnaire', 2)
('boston', 1)
('correction', 1)
('0\\.72\\\xe2\\\x80\\\x934\\.05', 2)
('null', 2)
('1\\.11', 4)
('1\\.12', 2)
('0\\.44\\\xe2\\\x80\\\x931\\.41', 2)
('relationship', 26)
('apolipoproteins', 6)
('current smoker', 2)
('chest', 2)
('potential', 1)
('1\\.33\\\xe2\\\x80\\\x936\\.00', 2)
('1\\.61', 4)
('provoked', 199)
('modifier', 5)
('explanation', 2)
('continuous', 4)
('altered', 2)
('investigations', 1)
('measures', 7)
('77', 14)
('76', 10)
('significant', 23)
('whs', 3)
('measured', 9)
('factorial design', 1)
('78', 18)
('3 days', 2)
('kg', 13)
('observation', 9)
('0\\.0013', 2)
('informed consent', 1)
('0\\.54\\\xe2\\\x80\\\x931\\.79', 2)
('factor viii', 2)
('traditional', 1)
('unadjusted', 10)
('randomized trial', 1)
('chances', 2)
('\\/dl', 56)
('impact', 2)
('ratio', 113)
('committee', 4)
('basel', 27)
('hrs', 9)
('only', 10)
('score', 6)
('lipids', 13)
('factor', 11)
('3\\.58', 5)
('permission', 2)
('overall', 6)
('125', 2)
('report', 28)
('129', 2)
('protein c', 26)
('secondary', 3)
('approach', 2)
('median', 5)
('alteration', 6)
('activity', 1)
('switzerland', 1)
('nitrogen', 1)
('0\\.81', 10)
('0\\.80', 6)
('0\\.47\\\xe2\\\x80\\\x931\\.43', 2)
('national', 1)
('observed', 27)
('individual', 2)
('result', 10)
('surgery', 5)
('immobilization', 1)
('subject', 3)
('3', 378)
('0\\.31', 6)
('0\\.34', 2)
('0\\.35', 2)
('computed tomography', 2)
('angiogram', 2)
('stratified', 8)
('variability', 2)
('tables', 2)
('initially', 3)
('analyzer', 3)
('incident', 11)
('p-value', 12)
('hypothesis', 4)
('20', 20)
('problem', 2)
('study protocol', 1)
('cox', 8)
('1\\.69\\\xe2\\\x80\\\x937\\.58', 5)
('variance', 4)
('placebo', 1)
('expression', 1)
('ci', 239)
('cancer', 4)
('cox proportional hazards models', 2)
('medical history', 2)
('excess', 2)
('mutations', 1)
('sampling', 4)
('60', 28)
('61', 19)
('antithrombin iii', 2)
('64', 6)
('65', 16)
('66', 18)
('67', 20)
('table', 24)
('basis', 2)
('addition', 2)
('0\\.0028', 2)
('thrombotic', 6)
('mean', 12)
('treatment', 14)
('direction', 2)
('hemostasis', 2)
('bmi', 9)
('most significant', 2)
('smoking', 16)
('novel', 1)
('evaluated', 3)
('n', 2594)
('aim', 1)
('healthy', 4)
('ongoing', 1)
('hdl', 68)
('study', 26)
('trend analysis', 4)
('models\\.', 4)
('physicians', 2)
('characteristics', 6)
('0\\.41', 6)
('0\\.40', 4)
('reports', 10)
('endpoints', 2)
('regression', 4)
('cohort', 16)
('different', 2)
('baseline', 26)
('trial', 4)
('recurrent', 1)
('same', 1)
('prothrombin', 2)
('randomization', 2)
('largest', 2)
('modification', 1)
('events', 23)
('conflict', 5)
('higher', 5)
('conflicting', 3)
('decedent', 2)
('literature', 2)
('reporting', 6)
('effect', 18)
('possible', 6)
('levels', 83)
('i-', 4)
('kin', 20)
('1\\.05', 2)
('1\\.02', 6)
('recent', 1)
('lower', 3)
('apolipoproteins b', 3)
('confidence intervals', 16)
('database', 2)
('changes', 2)
('quartile', 2)
('well', 9)
('cardiovascular events', 1)
('analysis', 26)
('person', 18)
('therapy', 71)
('model', 14)
('hospital', 5)
('venous thromboembolic event', 2)
('46\\.2\\\xe2\\\x80\\\x9358\\.4', 10)
('percent', 4)
('adjusted', 45)
('end point', 6)
('incidence rate', 24)
('study population', 4)
('venous thromboembolism', 13)
('death', 4)
('sample size', 4)
('apolipoprotein b', 6)
('\\?', 472)
('\\<', 63)
('\\%', 141)
('4', 338)
('plasma', 2)
('\\(', 479)
('\\)', 479)
('associations', 2)
('0\\.66', 12)
('march', 1)
('increased', 30)
('0\\.61', 6)
('\\[', 51)
('general population', 2)
('finding', 2)
('0\\.71\\\xe2\\\x80\\\x932\\.22', 2)
('background', 1)
('ventilation-perfusion scan', 2)
('height', 2)
('0\\.76\\\xe2\\\x80\\\x932\\.26', 2)
('case-control study', 4)
('59', 18)
('58', 52)
('standardization', 1)
('55', 33)
('hdl-c', 68)
('57', 13)
('b100', 28)
('51', 10)
('50', 17)
('53', 24)
('52', 10)
('specific', 5)
('either', 16)
('54', 24)
('roche diagnostics', 2)
('reduced', 5)
('malignancy', 4)
('methods', 2)
('calibrator', 1)
('114', 18)
('trends', 18)
('110', 2)
('113', 4)
('112', 2)
('low-density', 10)
('119', 4)
('0\\.56\\\xe2\\\x80\\\x931\\.95', 2)
('opposite', 2)
('71', 16)
('fragments', 2)
('limitations', 4)
('0\\.91', 4)
('0\\.92', 10)
('meta-analysis', 1)
('lipid', 93)
('0\\.96', 8)
('0\\.97', 10)
('0\\.98', 8)
('0\\.99', 12)
('biomarkers', 31)
('factor vii', 4)
('panel', 2)
('comparison', 2)
('statistically significant', 17)
('range', 48)
('tailed', 2)
('confidence interval', 18)
('0\\.06', 6)
('0\\.04', 4)
('0\\.03', 6)
('0\\.02', 10)
('ldl cholesterol', 2)
('2\\.88', 3)
('presence', 2)
('70', 19)
('blood samples', 1)
('2\\.82', 2)
('ultrasound', 2)
('lung', 1)
('proportional', 4)
('autopsy', 2)
('initial', 5)
('0\\.43\\\xe2\\\x80\\\x931\\.33', 2)
('long', 4)
('clinical', 2)
('1\\.9', 18)
('1\\.5', 25)
('1\\.4', 41)
('1\\.1', 50)
('1\\.0', 132)
('1\\.3', 42)
('1\\.2', 35)
('medical records', 2)
('complete', 5)
('hr', 49)
('lipid level', 22)
('ht', 43)
('0\\.001', 4)
('highest', 8)
('0\\.007', 2)
('deep vein thrombosis', 6)
('characteristic', 8)
('prospective cohort study', 1)
('chi-square test', 4)
('iqr', 2)
('cis', 2)
('incidence', 32)
('distribution', 4)
('similar', 8)
('clear', 4)
('follow up', 13)
('deaths', 2)
('evidence', 3)
('follow-up', 14)
('statistical significance', 4)
('triglycerides', 28)
('epidemiological', 1)
('48', 10)
('49', 16)
('46', 26)
('triglyceride level', 5)
('44', 10)
('42', 19)
('43', 18)
('40', 14)
('41', 18)
('5', 558)
('test', 34)
('conclusion', 3)
('users', 99)
('models', 8)
('time', 10)
('important', 8)
('massachusetts', 2)
('variable', 16)
('\xe2\x80\x93', 334)
('hazard ratio', 105)
('age', 25)
('portion', 7)
('diagnosis', 6)
('0\\.31\\\xe2\\\x80\\\x930\\.97', 4)
